Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ
Tytuł pozycji:

Emerging role of IL-6 and NLRP3 inflammasome as potential therapeutic targets to combat COVID-19: Role of lncRNAs in cytokine storm modulation.

Tytuł :
Emerging role of IL-6 and NLRP3 inflammasome as potential therapeutic targets to combat COVID-19: Role of lncRNAs in cytokine storm modulation.
Autorzy :
Paniri A; Student Research Committee, Babol University of Medical Sciences, Babol, Iran; Genetics Department, Faculty of Medicine, Babol University of Medical Sciences, Babol, Iran.
Akhavan-Niaki H; Genetics Department, Faculty of Medicine, Babol University of Medical Sciences, Babol, Iran; Zoonoses Research Center, Pasteur Institute of Iran, Amol, Iran. Electronic address: .
Pokaż więcej
Źródło :
Life sciences [Life Sci] 2020 Sep 15; Vol. 257, pp. 118114. Date of Electronic Publication: 2020 Jul 18.
Typ publikacji :
Journal Article; Review
Język :
English
Imprint Name(s) :
Publication: <2008->: Amsterdam : Elsevier
Original Publication: Oxford; Elmsford, N. Y. [etc.] Pergamon Press.
MeSH Terms :
Betacoronavirus/*genetics
Coronavirus Infections/*immunology
Interleukin-6/*immunology
Pneumonia, Viral/*immunology
RNA, Long Noncoding/*physiology
Anti-Inflammatory Agents/pharmacology ; Betacoronavirus/immunology ; Betacoronavirus/metabolism ; Coronavirus Infections/metabolism ; Cytokines/genetics ; Cytokines/immunology ; Humans ; Inflammasomes/immunology ; Inflammation/immunology ; Interleukin-6/metabolism ; Interleukin-6/pharmacology ; NLR Family, Pyrin Domain-Containing 3 Protein/immunology ; Pandemics ; Pneumonia, Viral/metabolism ; RNA, Long Noncoding/genetics
Contributed Indexing :
Keywords: COVID-19; Cytokine release syndrome; Drug; Inflammasome; Inflammation; SARS-CoV-2
Substance Nomenclature :
0 (Anti-Inflammatory Agents)
0 (Cytokines)
0 (Inflammasomes)
0 (Interleukin-6)
0 (NLR Family, Pyrin Domain-Containing 3 Protein)
0 (NLRP3 protein, human)
0 (RNA, Long Noncoding)
SCR Disease Name :
COVID-19
Entry Date(s) :
Date Created: 20200722 Date Completed: 20200929 Latest Revision: 20200929
Update Code :
20201023
PubMed Central ID :
PMC7368418
DOI :
10.1016/j.lfs.2020.118114
PMID :
32693241
Czasopismo naukowe
The world has witnessed a high morbidity and mortality caused by SARS-CoV-2, and global death toll is still rising. Exaggerated inflammatory responses are thought to be more responsible for infiltrated immune cells accumulation, organ damage especially lung, dyspnea, and respiratory failure rather than direct effect of viral replication. IL-6 and NLRP3 inflammasome are the major immune components in immune responses stimulation upon pathogen infection. It's noteworthy that the function and expression of these components are remarkably influenced by non-coding RNAs including long non-coding RNAs. Given the potential role of these components in organ damage and pathological manifestations of patients infected with COVID-19, their blockage might be a hopeful and promising treatment strategy. Notably, more study on long non-coding RNAs involved in inflammatory responses could elevate the efficacy of anti-inflammatory therapy. In this review we discuss the potential impact of IL-6 and NLRP3 inflammasome blocker drugs on inflammatory responses, viral clearance, and pathological and clinical manifestations. Collectively, anti-inflammatory strategy might pave the way to diminish clinical and pathological manifestations and thereby discharging patients infected with COVID-19 from hospital.
(Copyright © 2020 Elsevier Inc. All rights reserved.)

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies